Which of the following statements concerning levodopa (Duodopa) and carbidopa (Lodosyn) for Parkinson's disease is FALSE?

A. They treat only the symptoms of Parkinson's disease: Levodopa/carbidopa alleviates motor symptoms such as bradykinesia, rigidity, and tremor but does not alter the underlying neurodegenerative process. Symptomatic relief is the primary therapeutic goal. B. They reverse the effects of Parkinson's disease: Levodopa/carbidopa cannot reverse the loss of dopaminergic neurons in the substantia nigra. The medication improves motor function but does not halt or restore disease progression, making this statement false. C. Carbidopa permits higher levels of levodopa to be available in the brain: Carbidopa inhibits peripheral decarboxylation of levodopa, allowing more levodopa to cross the blood-brain barrier and reducing peripheral side effects like nausea and hypotension. D. Patients eventually require more frequent dosing intervals: Over time, patients often experience “wearing-off” phenomena due to disease progression and changes in drug metabolism, necessitating shorter dosing intervals or adjunct therapies to maintain symptom control.